Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM)

被引：0
|
作者：
Scheid, C. [1 ]
Roellig, C. [2 ]
Weisel, K. [3 ]
Salwender, H-J [4 ]
Gramatzki, M. [5 ]
Edmaier-Schroeger, K. [6 ]
Sy, O. [7 ]
Goldschmidt, H. [8 ]
机构：
[1] Univ Klinikum Koln, Cologne, Germany
[2] Univ Dresden, Dresden, Germany
[3] Univ Tubingen, Tubingen, Germany
[4] Asklepios Klin Hamburg, Hamburg, Germany
[5] Univ Schleswig Holstein, Kiel, Germany
[6] Bristol Myers Squibb, Munich, Germany
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P571
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [31] ELOQUENT-2: Extended safety and efficacy follow-up of the phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma
    Dimopoulos, M.
    Lonial, S.
    White, D.
    Moreau, P.
    Palumbo, A.
    San Miguel, J.
    Shpilberg, O.
    Anderson, K.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen-Nativ, H.
    Mateos, M-V
    Reece, D.
    Beksac, M.
    Bleickardt, E.
    Poulart, V.
    Katz, J.
    Singhal, A.
    Richardson, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 6 - 7
  • [32] POMALIDOMIDE (POM) plus LOW-DOSE DEXAMETHASONE (LODEX) AFTER SECOND-LINE LENALIDOMIDE (LEN)-BASED TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PROGRESSION-FREE SURVIVAL ANALYSIS
    Siegel, D. S.
    Schiller, G. J.
    Song, K.
    Agajanian, R.
    Stockerl-Goldstein, K.
    Kaya, H.
    Sebag, M.
    Reu, F. J.
    Malek, E.
    Talamo, G.
    Mouro, J.
    Chung, W.
    Srinivasan, S.
    Qian, M.
    Rizvi, S.
    Thakurta, A.
    Bahlis, N. J.
    HAEMATOLOGICA, 2017, 102 : 511 - 511
  • [33] Cost per Progression Free Survival (PFS) of Daratumumab, Elotuzumab, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (DRd, ERd, KRd, IRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Santana, Pamela
    Saad, Ricardo
    Kolanian, Adrielle
    Fioratti, Cyntia
    Junqueira, Marcela
    Decimoni, Tassia
    BLOOD, 2019, 134
  • [34] PHASE (PH) I/II STUDY OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE (LEN/DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM): UPDATED PH II RESULTS AND PH I/II LONG TERM SAFETY
    Facon, T.
    Richardson, P.
    Jagannath, S.
    Moreau, P.
    Jakubowiak, A.
    Raab, M.
    Vij, R.
    White, D.
    Reece, D.
    Benboubker, L.
    Zonder, J.
    Deng, W.
    Bleickardt, E.
    Singhal, A.
    Lonial, S.
    HAEMATOLOGICA, 2013, 98 : 319 - 319
  • [35] Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
    Weisel, Katja
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Lord-Bessen, Jennifer
    Yip, Christine
    Greenwood, Mike
    Tang, Jackson
    Cavo, Michele
    HEMASPHERE, 2023, 7 (03): : E843
  • [36] Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety
    Lonial, Sagar
    Jagannath, Sundar
    Moreau, Philippe
    Jakubowiak, Andrzej J.
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    Bleickardt, Eric
    Reece, Donna Ellen
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Deng, Wei
    Singhal, Anil K.
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma ( RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial
    Weisel, Katja
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Lord-Bessen, Jennifer
    Yao, David
    Yip, Christine
    Greenwood, Mike
    Tang, Jackson
    Cavo, Michele
    BLOOD, 2021, 138
  • [38] Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Di Bacco, Alessandra
    Bahlis, Nizar J.
    Munshi, Nikhil C.
    Avet-Loiseau, Herve
    Masszi, Tamas
    Viterbo, Luisa
    Pour, Ludek
    Ganly, Peter
    Cavo, Michele
    Langer, Christian
    Kumar, Shaji
    Rajkumar, S. Vincent
    Berg, Deborah
    Lin, Jianchang
    Li, Bin
    Badola, Sunita
    Shen, Lei
    Zhang, Jacob
    Wang, Ling
    Esseltine, Dixie-Lee
    Luptakova, Katarina
    de Velde, Helgi van
    Richardson, Paul G.
    Moreau, Philippe
    BLOOD, 2016, 128 (22)
  • [39] Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study
    Bahlis, Nizar
    Samaras, Christy
    Reece, Donna
    Sebag, Michael
    Matous, Jeffrey
    Berdeja, Jesus
    Shustik, Jesse
    Schiller, Gary
    Ganguly, Siddhartha
    Song, Kevin
    Seet, Christopher
    Acosta-Rivera, Mirelis
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Liu, Hongjuan
    Gentili, Christian
    Siegel, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S162 - S162
  • [40] Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN plus DEX) versus LEN plus DEX only in relapsed/refractory multiple myeloma (R/R MM): A comparative cost-effectiveness analysis.
    Obeng-Kusi, Mavis
    Arku, Daniel
    Alrawashdh, Neda
    Choi, Briana
    Alkhatib, Nimer S.
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345